Data as of 4:00pm ET
| -0.03 / -1.46%|
The 1 analysts offering 12-month price forecasts for Protalix Biotherapeutics Inc have a median target of 2.00, with a high estimate of 2.00 and a low estimate of 2.00. The median estimate represents a -0.99% decrease from the last price of 2.02.
The current consensus among 2 polled investment analysts is to Hold stock in Protalix Biotherapeutics Inc. This rating has held steady since January, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.